REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
16/03/2026
Voltar para busca
Dado oficial do USPTO
FARMABIOS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
42
Atualização mais recente
17/03/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 42
Data de depósito
21/04/2020
Data de registro
16/03/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
16/03/2021
Última transação
17/03/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
35
Localização do titular
IT
Examinador
BRADLEY, EVELYN
Unidade examinadora
L40
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the stylized wording "FARMABIOS" with two chevrons.
Titulares e representantes
Titulares
Farmabios S.p.A.
Representantes
Michael N. Mercanti LUCAS & MERCANTI, LLP
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Anti-inflammatory preparations; cholesterol reducers; steroids; respiratory stimulants; cardiotonic; chemotherapeutics; chemico-pharmaceutical preparations for the treatment of autoimmune disordersinflammationsasthmapsoriasiscancerdermatitis; pharmaceuticals for the treatment of autoimmune disordersinflammationsasthmapsoriasiscancer and dermatitis
Classe 42
Analysis and evaluation of product development; scientific analysis in the field of pharmaceuticalsactive pharmaceutical ingredientsdrug substances; chemistry consultation; consultancy relating to pharmaceutical research and development; product development consultation; consultancy relating to industrial research in the field of active pharmaceutical ingredients and new chemical entities; technical consultancy relating to product development; design and development of industrial products in the field of active pharmaceutical ingredientsdrug substances in particular steroidshigh potent substancescannabinoidsantineoplastics; conducting of scientific feasibility studies; conducting of technical feasibility studies in the field of chemical research for the synthesis of existing and new chemical entities; chemical research; research relating to technology; development of new products for others; research and development for others with regard to new products; pharmaceutical research and development; scientific and industrial research in the field of active pharmaceutical ingredientsdrug substances in particular steroidshigh potent substancescannabinoidsantineoplastics; laboratory research in the field of chemistry; industrial analysis and research services in the field of chemistry; preparation of scientific reports; preparation of technical reports relating to chemical research for the synthesis of existing and new chemical entities; engineering feasibility studies; development of new technology for others in the field of chemicalpharmaceuticalenzymatic reactions; development of industrial processes for others in the field of chemicalpharmaceuticalenzymatic reactions; development of new industrial products for others
Publicações
Histórico de despachos e eventos da marca no USPTO.
42 publicações encontradas
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/12/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/12/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/12/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
21/02/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
06/11/2021
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
11/07/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
22/06/2021
FIMP
FINAL DISPOSITION PROCESSED
22/06/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
16/06/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
16/03/2021
GPNX
NOTIFICATION PROCESSED BY IB
10/01/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
29/12/2020
PUBO
PUBLISHED FOR OPPOSITION
29/12/2020
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
23/12/2020
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
23/12/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/12/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
21/11/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
21/11/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
21/11/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
21/11/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
21/11/2020
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
12/11/2020
GNFR
FINAL REFUSAL E-MAILED
12/11/2020
CNFR
FINAL REFUSAL WRITTEN
12/11/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/10/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/10/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/10/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
30/09/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
30/09/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
30/09/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
30/09/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
30/09/2020
RFNT
REFUSAL PROCESSED BY IB
27/09/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/09/2020
RFRR
REFUSAL PROCESSED BY MPU
24/08/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
19/07/2020
CNRT
NON-FINAL ACTION WRITTEN
18/07/2020
DOCK
ASSIGNED TO EXAMINER
13/07/2020
MAFR
APPLICATION FILING RECEIPT MAILED
23/06/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
19/06/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
18/06/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace FARMABIOS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.